Taylor Morrison
TMHC
$71.50
-0.07%
Taylor Morrison Home Corporation is a prominent American residential construction company that designs, builds, and sells single-family and multi-family homes, primarily in high-growth markets across the East, Central, and West regions of the United States. The company operates as a significant national homebuilder with a focus on entry-level, move-up, and resort lifestyle buyers, deriving the majority of its revenue from its West segment. The current investor narrative centers on the stock's pronounced underperformance relative to the broader market, driven by concerns over the cyclical housing sector's sensitivity to interest rates and economic conditions, which has sparked debate about its valuation as a potential deep-value opportunity or a value trap amidst a challenging macro environment.…
TMHC
Taylor Morrison
$71.50
Related headlines
Investment Opinion: Should I buy TMHC Today?
Rating & Thesis: Hold. TMHC presents a classic 'value vs. value trap' dilemma where compellingly cheap valuation and a fortress balance sheet are counterbalanced by severe cyclical headwinds and abysmal price momentum, making the timing for a new purchase highly uncertain. The limited analyst coverage provides no clear price target anchor to build conviction.
Supporting Evidence: The Hold rating is supported by four key data points: 1) The ultra-low trailing P/E of 7.45x suggests deep undervaluation if earnings are sustainable. 2) The strong balance sheet (D/E 0.37, Current Ratio 6.24) provides downside protection. 3) Analyst consensus expects forward EPS of $6.53, implying potential earnings growth. 4) However, the stock's high beta of 1.512 and -20.43% 3-month return demonstrate extreme volatility and negative momentum that could persist.
Risks & Conditions: The two biggest risks are a deeper-than-expected housing recession and the stock remaining a 'value trap' with no catalyst for multiple re-rating. This Hold would upgrade to a Buy if the price demonstrates sustained technical support above the $54.58 low and/or forward P/E compresses below 7x on stable earnings estimates. It would downgrade to a Sell if the 52-week low is decisively broken on high volume or if analyst EPS estimates are revised downward by more than 10%. Relative to its own evident distress and sector cyclicality, the stock appears fairly valued to slightly undervalued, but not without significant near-term risk.
Sign up to view all
TMHC 12-Month Price Forecast
The assessment is neutral due to the high-contrast picture: deeply attractive value metrics are completely overshadowed by powerful negative momentum and macro risks. The strong balance sheet prevents a bearish stance, but the lack of a visible near-term catalyst and the stock's tendency to underperform the market (relative strength -32.23 over 1 year) argue against bullishness. The stance would upgrade to bullish on a confirmed technical reversal above key resistance (e.g., sustained move above $65) coupled with stabilizing interest rate expectations. It would downgrade to bearish on a breakdown below the $54.58 support level on worsening housing data.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Taylor Morrison's 12-month outlook, with a consensus price target around $92.95 and implied upside of +30.0% versus the current price.
Average Target
$92.95
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$57 - $93
Analyst target range
Analyst coverage for TMHC is limited, with only 5 analysts providing estimates, which is indicative of a mid-cap stock with lower institutional visibility that can lead to higher volatility and less efficient price discovery. The consensus estimates point to an average EPS of $6.53 for the coming period, with a range from a low of $5.12 to a high of $7.10, while revenue is expected to average around $7.1 billion; the relatively tight EPS range suggests some consensus on the earnings outlook, though the small analyst pool limits the strength of this signal. Specific analyst recommendations, price targets, and the implied upside or downside from the current price are not available in the provided data, making it impossible to gauge the bullish or bearish sentiment from the street; the absence of this key data further underscores the stock's status as having insufficient mainstream analyst coverage for a clear market signal.
Bulls vs Bears: TMHC Investment Factors
The evidence currently tilts bearish, primarily due to the stock's severe and persistent technical breakdown, significant underperformance, and its high sensitivity to a challenging macro environment for housing. The bull case rests on a compelling valuation and strong balance sheet, which are classic value investor signals. The single most important tension in the investment debate is whether the current ultra-low valuation (P/E ~7.5x) accurately prices in an imminent cyclical downturn (bear view) or represents an excessive market overreaction creating a deep-value opportunity (bull view). The resolution hinges almost entirely on the future path of interest rates and housing demand.
Bullish
- Deeply Discounted Valuation: The stock trades at a trailing P/E of 7.45x and a forward P/E of 8.54x, which is exceptionally low for a profitable company with a 9.63% net margin. This valuation, coupled with a price-to-cash-flow of 6.88x, suggests the market is pricing in severe cyclical distress, creating a potential margin of safety for value investors.
- Strong Balance Sheet & Liquidity: The company exhibits robust financial health with a low debt-to-equity ratio of 0.37 and a very strong current ratio of 6.24. This conservative leverage and ample liquidity provide a significant buffer to navigate a potential housing downturn without a solvency crisis.
- Analyst EPS Growth Expectations: Despite limited coverage, the 5 analysts covering TMHC project an average EPS of $6.53 for the coming period, with a high estimate of $7.10. This forward earnings power, if realized, would imply significant earnings growth from the trailing EPS base, which is not reflected in the current depressed share price.
- Operational Profitability: The company maintains healthy operational metrics, including a 13.98% operating margin and a 12.40% return on equity. These figures indicate the underlying business is fundamentally sound and efficiently generating profits, even amidst sector-wide headwinds.
Bearish
- Severe Technical & Relative Underperformance: The stock is down 20.43% over three months and 7.04% over one year, starkly underperforming the S&P 500 by 28.85 and 32.23 percentage points, respectively. It currently trades just 0.4% above its 52-week low of $54.58, signaling persistent selling pressure and a complete lack of positive momentum.
- High Cyclical & Macro Sensitivity: As a homebuilder in the Consumer Cyclical sector, TMHC is highly exposed to interest rate risk and economic cycles. This is confirmed by its high beta of 1.512, meaning it is over 50% more volatile than the market, amplifying downside during risk-off periods.
- Limited Analyst Coverage & Visibility: With only 5 analysts providing estimates, TMHC suffers from lower institutional visibility, which can lead to inefficient price discovery and higher volatility. The absence of specific price targets and recommendations from the street further muddies the investment signal.
- Revenue Growth Uncertainty: The analysis lacks specific quarterly revenue and growth rate data, creating uncertainty about the company's current top-line trajectory. While analyst revenue estimates average $7.1B, the inability to confirm growth acceleration or deceleration is a material blind spot.
TMHC Technical Analysis
The stock is in a pronounced downtrend, having declined 20.43% over the last three months and 7.04% over the past year, significantly underperforming the S&P 500 which gained 25.19% over the same one-year period. Currently trading at $54.79, the price sits just 0.4% above its 52-week low of $54.58, positioning it at the extreme lower bound of its annual range, which typically signals either a deep-value opportunity or fundamental distress, though the severe underperformance suggests the latter is a primary market concern. Recent momentum remains weak and negative, with the stock down 5.11% over the past month, which contrasts sharply with the S&P 500's 5.6% gain, resulting in a stark relative strength reading of -10.71; this one-month decline continues the longer-term bearish trajectory, indicating no signs of a near-term reversal and confirming sustained selling pressure. Key technical support is firmly established at the 52-week low of $54.58, while resistance lies at the 52-week high of $72.50; a decisive breakdown below $54.58 could trigger accelerated selling, whereas any recovery would need to contend with significant overhead supply. The stock's beta of 1.512 confirms it is over 50% more volatile than the market, which amplifies both downside risk and potential upside during sector recoveries, necessitating careful risk management for investors.
Beta
1.51
1.51x market volatility
Max Drawdown
-23.8%
Largest decline past year
52-Week Range
$54-$73
Price range past year
Annual Return
+28.0%
Cumulative gain past year
| Period | TMHC Return | S&P 500 |
|---|---|---|
| 1m | +18.4% | +5.4% |
| 3m | +12.5% | +10.9% |
| 6m | +14.0% | +11.0% |
| 1y | +28.0% | +28.1% |
| ytd | +21.5% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMHC Fundamental Analysis
Revenue trajectory analysis is constrained as specific quarterly revenue and growth rate figures are not available in the provided data; however, analyst estimates for future revenue average approximately $7.1 billion, suggesting the market anticipates a stable top-line, though the lack of recent reported figures limits insight into current growth acceleration or deceleration trends. The company is profitable, with a trailing net margin of 9.63% and a gross margin of 23.03%; the operating margin stands at 13.98%, indicating healthy operational efficiency, though the absence of multi-quarter margin data prevents a clear assessment of whether these profitability metrics are expanding or compressing. Balance sheet health appears robust, with a strong current ratio of 6.24 signaling ample short-term liquidity, a conservative debt-to-equity ratio of 0.37 reflecting a low reliance on financial leverage, and a return on equity of 12.40% demonstrating decent capital efficiency; the price-to-cash-flow ratio of 6.88 suggests the market is valuing the company's cash generation modestly, which aligns with the overall value-oriented multiples.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMHC Overvalued?
Given the company's positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 7.45x and a forward PE of 8.54x; the slight premium of the forward multiple suggests the market expects modest earnings growth, though the low absolute level indicates deeply discounted expectations. Compared to sector averages, which are not provided in the data, a definitive premium or discount cannot be quantified; however, a sub-10x PE is generally considered low for a profitable company, potentially signaling a significant discount unless justified by poor growth prospects or high cyclical risk. Historical context for the stock's own valuation range is unavailable due to missing historical ratios data, preventing an assessment of whether the current multiple is at the top or bottom of its historical band; this lack of historical comparison limits the ability to determine if current levels represent a cyclical low or a new normal.
PE
7.5x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
6.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is not leverage or liquidity—the balance sheet is strong—but earnings volatility inherent to the cyclical homebuilding business. The company's profitability (9.63% net margin) is directly exposed to swings in material costs, labor availability, and buyer affordability. A key operational risk is revenue concentration, with the majority derived from the West segment, making the company vulnerable to regional economic downturns or regulatory changes in key states like California or Arizona.
Market & Competitive Risks: The paramount market risk is valuation compression. Trading near a 52-week low at a P/E of 7.45x, the stock already reflects deep pessimism, but a prolonged housing slump could lead to earnings declines that keep the multiple depressed or even cause it to expand on lower earnings, a scenario known as a 'value trap.' Competitive risks are high in a slowing market, as larger builders may engage in price wars to maintain volume, pressuring TMHC's already modest 23.03% gross margin. The stock's high beta of 1.512 confirms it will be disproportionately impacted by broader market sell-offs.
Worst-Case Scenario: The worst-case scenario involves a sharp economic recession coupled with persistently high mortgage rates, leading to a multi-year downturn in new home sales. This would cause order cancellations, inventory writedowns, and a collapse in earnings below the analyst low EPS estimate of $5.12. In this adverse scenario, the stock could re-test and break its 52-week low, potentially falling to levels implied by a P/E of 5-6x on depressed earnings. From the current price of $54.79, a realistic severe downside could be a 25-30% decline, targeting a range of $38-$41, which would represent a drawdown exceeding the recent -23.8% max drawdown.
FAQ
The key risks are: 1) Macro/Cyclical Risk: The stock's fate is tied to interest rates and the housing cycle, evidenced by its 1.512 beta and 7.04% annual loss during a strong market. 2) Valuation Trap Risk: The stock may stay cheap indefinitely if the housing slowdown is prolonged, despite its low P/E. 3) Earnings Volatility Risk: Analyst EPS estimates range from $5.12 to $7.10, highlighting uncertainty; misses could trigger further selling. 4) Low Visibility Risk: Coverage by only 5 analysts means less institutional support and potentially sharper reactions to news. The macro risk is the most severe and immediate.
The 12-month forecast is highly scenario-dependent. The base case (55% probability) sees range-bound trading between $58 and $65, assuming stable but muted housing conditions and EPS meeting the $6.53 consensus. The bull case (25% probability) targets a recovery to $68-$72.50 on falling rates and earnings beats. The bear case (20% probability) warns of a drop to $45-$54.58 if a recession hits and earnings fall towards the $5.12 low estimate. The base case is most likely, centered on analyst EPS estimates, but the wide range underscores the stock's high uncertainty and volatility.
Based on absolute multiples, TMHC appears significantly undervalued. It trades at a trailing P/E of 7.45x, a forward P/E of 8.54x, and a price-to-cash-flow of 6.88x—levels typically associated with deep value. However, valuation must be contextualized by risk. The market is applying this deep discount due to the stock's high cyclical risk (beta 1.512) and poor momentum. Therefore, while statistically cheap, the stock may be fairly valued or even a 'value trap' if the anticipated housing downturn materializes and compresses earnings. The valuation implies the market expects stagnant or declining future profits.
TMHC is a high-risk, high-potential-reward stock that may be a good buy only for specific investors. For value-focused, patient investors with a multi-year horizon and high risk tolerance, its low P/E of 7.45x and strong balance sheet (D/E 0.37) present a compelling deep-value case. However, for most investors, it is not a good buy currently due to its severe downtrend, -20.43% 3-month loss, high beta of 1.512, and sensitivity to uncertain interest rate movements. Timing is exceptionally difficult, making it more suitable for watchlists than immediate purchase.
TMHC is unsuitable for short-term trading due to its high volatility (beta 1.512), negative momentum, and lack of near-term catalysts. It is a speculative long-term investment for investors betting on a full housing cycle recovery. A minimum holding period of 3-5 years is suggested to potentially ride out the cyclical downturn and benefit from eventual mean reversion in valuation and sector fortunes. The stock pays no dividend, eliminating an income component, so the entire thesis rests on capital appreciation from a cyclical turnaround, which is inherently a longer-term proposition.